Make sure to save the date for the ABCARA Annual Scientific Meeting, being held at the Adelaide Convention Centre in South Australia on Friday the 28th of August 2026! Head to the website and subscribe to the email list to keep up with news, updates and speaker announcements.

Do you want the opportunity to present your work in a talk or as a poster in front of brain cancer experts? Get your abstracts in before they close on June 30th for the chance to win $250 for best poster. Guidelines are on our website. See you in Adelaide in August!

Our final invited speaker is Dr Yanan Zhang, Entrepreneur Fellow and Postdoc at University Hospital Zurich, and Co‑founder of ZuriEV. She develops EV‑based liquid biopsy technologies for cancer diagnosis and monitoring. ABCARA 2026 abstracts close June 30!

Prof Lenka Munoz joins us as our next invited speaker. She leads the Glioblastoma Drug Discovery Lab at the Charles Perkins Centre and studies new targets and drug mechanisms in glioblastoma. ABCARA 2026 abstracts close June 30!

The research community of ABCARA join the rest of Australia as we mourn the passing of Professor Richard Scolyer. Our thoughts are with his family and close friends. His memory motivates us to continue the research required to defeat this terrible disease.

Welcome invited speaker, John de Groot, Division Chief of Neuro-Oncology at UCSF. An internationally recognised leader in brain tumour treatment including immunotherapy, focused ultrasound, and targeted therapies, specialising in treatment of adults with brain tumours.

Our next invited speaker is Dr Johannes vom Berg! He’s a group leader at the Institute of Laboratory Animal Science, and Co-founder and CSO of InCephalo Therapeutics. His research focuses on local immunotherapy of brain tumours and tailoring biologics to this delivery route.

Welcome the next invited speaker, Dr Gregory Stein! The CEO of Curtana Pharmaceuticals with experience as a clinician and life science executive, and in diagnostics, medical devices, pharmaceuticals and biotech. Head to our website to register for ABCARA 2026 to see our speakers.

Welcome invited speaker Eng-Siew Koh, radiation oncologist at Liverpool Cancer Therapy Centre, NSW. Her incredible expertise ranges in adult and paediatric neuro-oncology, haematological cancers, stereotactic radiotherapy, and cancer survivorship. Head to our website to register!

Our next invited speaker is Prof Cedric Bardy, ARC Future Fellow at Flinders, SAHMRI Group Lead and Founding Director of Brain Organoid Therapeutics. He’s internationally recognised for pioneering advances in the physiological complexity of human neural models in vitro.

Our first invited speaker is Dr Bingyang Shi, Chair Professor of Nanomedicine at UTS and a global leader in brain‑targeted drug delivery. His work spans nanomedicine and biomolecular engineering to develop next‑gen brain therapies. ABCARA 2026 registration is NOW OPEN.

Meet our second keynote speaker, Professor David Ashley! An internationally renowned neuro-oncologist, Prof Ashley has been the Director of the Preston Robert Tisch Brain Tumor Center, and is now returning to Australia as the CEO of the VCCC alliance and laboratory head at WEHI.

Registration and abstract submissions for ABCARA 2026 are NOW OPEN! Head to our website or scan the QR code for tickets and abstract submission guidelines. See you in Adelaide on the 28th of August!

Meet our first ABCARA 2026 keynote speaker: Professor Dieter Henrik Heiland, a leader in neurosurgery and spatial multi‑omics. Symposium registrations open May 7. Check our website for details and upcoming speaker announcements.

Head to the Hill Canberra 2025! - A huge shout-out to BTAA for organising the event and for the fearless leadership of BTAA Chair Craig Cardinal!! We truly appreciated the engagement and support of The Hon Mark Butler, Mr Andrew Wilkie MP and Prof Richard Scolyer AO.

Head to the Hill Canberra 2025!! - what a truly impactful day, thank you to the whole brain cancer community for your advocacy and for raising awareness to this critical issue. Braving the cold to fight for change!!!

ABCARA and COGNO are delighted to announce the launch of the OPAL study - a national, multi-site Phase 1 clinical trial of CT-179, a first-in-class orally bioavailable brain penetrant small molecule targeting OLIG2, a key protein associated with glioblastoma cancer stem cells.

Exciting news as @ABCARA_Online comes together with COGNO and @CurtanaPharma for the OPAL Clinical Trial in Glioblastoma Patients.